Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
Sagar Jayantilal DholariyaSiddhartha DuttaRagini SinghDeepak N ParchwaniAmit SonagraMehul KaliyaPublished in: Expert opinion on pharmacotherapy (2023)
= 0.0001) in comparison to placebo. The safety outcomes of bexagliflozin were consistent with the placebo arm. This study concluded that bexagliflozin seems to be a promising oral anti-diabetic drug for enhancing glycemic management in adult patients with T2DM.